Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Biotech-Perle kurz vor entscheidender Meilenstein-Meldung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
61 Leser
Artikel bewerten:
(0)

Research and Markets - High-Throughput Screening (HTS) Market to Reach $18 Billion by 2021 With Axxam, Perkinelmer & Tecan Group Dominating

DUBLIN, Dec 9, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "High-Throughput Screening Market - Forecast to 2021" report to their offering.

Market growth can be attributed to the growing adoption of open innovative models in the pharmaceutical and biotechnology industry and technological advancements like automation and miniaturization, increasing R&D spending and rising government funding. Emerging markets and growing research activities in toxicology and stem cells provide significant growth opportunities for the market. On the other hand, the high cost and time-consuming nature of HTS techniques are restraining the growth of this market during the forecast period.

The global high-throughput screening market is segmented on the basis of product and service, technology, application end user and region. Based on product and service, the high-throughput screening market is segmented into consumables and reagents, instruments, & software and services. Based on technology, the high-throughput screening market is segmented into cell-based assays; lab-on-a-chip, ultra high-throughput screening market, label-free technology and bioinformatics. The cell-based assays segment is subsegmented into 2D cell culture, 3D cell culture and perfusion cell culture.

North America is the largest market for high-throughput screening, followed by Europe and Asia-Pacific. However, Asia-Pacific and Latin America possess lucrative growth potential for the high-throughput screening market during the forecast period. This is mainly attributed to the increasing R&D spending; growing trend of outsourcing drug discovery services; growing public-private partnerships; and increasing government funding.

Companies Mentioned:

  • Agilent Technologies, Inc.
  • Aurora Biomed, Inc.
  • Axxam S.P.A.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Hamilton Company
  • Perkinelmer, Inc.
  • Sigma-Aldrich Corporation (A Division of Merck Millipore)
  • Tecan Group Ltd.
  • Thermo Fisher Scientific Inc.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 High-Throughput Screening Market, by Product & Service

8 High-Throughput Screening Market, by Technology

9 High-Throughput Screening Market, by Application

10 High-Throughput Screening Market, by End User

11 High-Throughput Screening Market, by Region

12 Competitive Landscape

13 Company Profiles

For more information about this report visit http://www.researchandmarkets.com/research/t9x4t3/highthroughput

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.